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The work aims to investigate the in vitro release, pharmacokinetics (PK), pharmacody-
namics (PD) and PKePD relationships of Salvianolic Acid B micro-porous osmotic pump
pellets (SalB-MPOPs) in angina pectoris New Zealand White (NZW) rabbits, compared with
those of SalB immediate-release pellets (SalB-IRPs). The SalB plasma concentrations and
Superoxide dismutase levels (PD index) were recorded continuously at predetermined time
interval after administration, and the related parameters were calculated by using Win-
Nonlin software. The release profile of MPOPs was more sustained than that of IRPs. PK
results indicated that the mean Cmax was significantly lower, the SalB plasma concentra-
tions were steadier, both area under concentration-time curve from 0 to 24 h (AUC0e24 h)
and from 0 to infinity (AUC0eN) were presented larger, and both the peak concentration
time (Tmax) and mean residence time (MRT) were prolonged for MPOPs, as compared with
those of IRPs. PD results suggested that peak drug effect (Emax) was lower and the equili-
bration rate constant (ke0) between the central compartment and the effect compartment
was higher of MPOPs vs. those of IRPs. PKePD relationships demonstrated that the effect-
concentration-time (ECT) course of MPOPs was clockwise hysteresis loop, and that of IRPs
was counter-clockwise hysteresis loop. Collectively, those results demonstrated that
MPOPs were potential formulations in treating angina pectoris induced by atherosclerosis.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved., Nanjing 210009, PR China. Tel.: þ86 25 83271293, þ86 15952038790 (mobile); fax: þ86 25
m, kansldong@163.com (J.-P. Liu).
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attractive dosage for many merits, such as cutting down side
effect by decreasing the drug plasma concentration fluctua-
tion, and reducing administration frequency to enhance the
compliance. Researchers usually evaluate the formulations by
PK parameters, such as Cmax, t1/2 and lower plasma drug
concentration fluctuation [1]. PK parameters were always
directly related to efficacy. However, in many cases, the rela-
tionship between plasma drug concentration and effect
magnitude is non-linear, and the real effect magnitude
couldn’t be estimated just by PK parameters [2]. PKePD
modeling can predict relevant parameters associated with
onset, magnitude and time courses of dose-concentration-
effect of a drug [3], thus verifying the rationality of the
formulation design. Meanwhile, PKePD modeling provides
better understanding of drug efficacy and safety in drug
development, its use could significantly reduce the cost in
both early and late drug development. It is therefore vitally
important to have a thorough understanding of the PKePD
relationships in designing controlled release system.
Salvianolic Acid B (SalB, Fig. 1), the highest-content
aqueous bioactive components extracted from the root of
Salvia miltiorrhiza Bunge, has many promising pharmacology
effects such as antioxidant, anti-hepatic fibrosis, anti-aging
and antitumor effects etc [4]. Its excellent antioxidant activ-
ity could reduce or even reverse the progression of athero-
sclerosis, so SalB has been widely used in the treatment of
cardiovascular disease [5]. However, there is only less than 1%
of initial drug plasma concentration in blood after 7 h intra-
venous injection due to the short half-lives and fast clearance
[6]. Meanwhile, it was suggested that SalB, which belongs to
biopharmaceutics classification system (BCS) Ⅲ, had low oral
bioavailability in vivo [7] probably because of its poor perme-
ation [8]. To enhance the bioavailability, ameliorating the
permeation and prolonging the durationwere well considered
in the past.
Efforts have been done mainly focusing on the two facts
mentioned above [9e14], such as SalB controlled porosity os-
motic pump tablets, PEGylated SalB liposomes and phospho-
lipids complex (SalB-PC), etc. While in the oral solid
formulations aspects,most of theworks only addressed one of
the shortcomings of the drug. Hence, in previous work [15],
SalB-PC pellets have been prepared by us, which enhanced theFig. 1 e The structure of Salvianolic Acid B.permeability and oral bioavailability of the drug. Furthermore,
once-a-day SalB-MPOPs were prepared successfully using
coating technology by evaluating in vitro release profiles and
in vivo absorption curves [16].
In the current research SalB-MPOPswere first prepared, the
formulationwas subsequently characterized by in vitro release
and the parameters of PK and PD in angina pectoris NZW
rabbits model induced by atherosclerosis, furthermore, the
PKePD relationship and action mechanisms of the SalB-
MPOPs were investigated by PKePD parameters and ECT
course, compared with those of SalB-IRPs.2. Materials and methods
2.1. Materials
SalB (98% pure) and SalB standard were purchased from Xi’an
Honson Biotechnology Co., Ltd. (Xi’an, China) and theNational
Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China), respectively. High-fat feed was
purchased from Jiangsu synergistic biological engineering Ltd
(Nanijing, China). SOD reagents box was provided by Nanjing
Jian cheng Bioengineering Institute (Nanijing, China); calcium
heparin was purchased from Changzhou Qianhong Bio-
pharma Co., Ltd (Changzhou, Jiangsu, China). Oil red O was
purchased from Sigma (Sigmae Aldrich Chemical Company,
Madrid, Spain), 5% gluconate solutionwas provided by JiangSu
Dahongying pharmaceutical Co., Ltd. (Nanjing, Jiangsu,
China). All other used reagents were analytical grade, but
mobile phase were chromatographic grade and purchased
from Chemical Reagent Co., Ltd. (Nanjing, China).
2.2. Preparation of pellets
SalB-IRPs of 800e1000 mm were composed of SalB-
phospholipids complex (SalB-PC, MCC, Kollidon CL-SF and
Flowlac100 at 30:40:15:15 (w/w/w/w)) in an extrusion-
spheronization apparatus (JBZ-300, Shenyang, China) [15].
Osmotic pressure agent was incorporated into the SalB-IRPs
composed materials and the 800e1000 mm SalB-MPOPs
starter cores were prepared as described above in prepara-
tion of SalB-IRPs. Subsequently, SalB-MPOPs were prepared by
coating the starter cores with aqueous dispersion containing
Poly(vinyl alcohol)-poly(ethylene glycol)(PVA-PEG) as a pore-
forming agent and Ethyl cellulose (EC) aqueous dispersion
(brand name, Surelease) using fluid-bed (JHQ-100; Shenyang,
China) [16]. Both SalB-IRPs and SalB-MPOPs containing 25 mg
SalB were sealed in hard gelatin capsules with a manual
capsule filling machine (CapsulCN, Zhejiang, China).
2.3. In vitro release tests
2.3.1. Quantitative analysis of SalB
All of the determinations of SalB content were done by using
HPLC and the system consisted of Shimadzu LC-20AB pump, a
Shimadzu SIL-20AC autosampler, a Shimadzu SPD-M20A
diode array detector (DAD) (Kyoto, Japan) and a Synergi
Hydro-RP C18 column (5 mm, 250 mm  4.6 mm, Phenomenex,
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 3 7e1 4 5 139USA) protected by a C18 Securityguard column (5 mm,
10 mm  4.6 mm, Kromasil, Sweden). The mobile phase was
methanol-acetonitrile-formic acid-double deionized water
(28:12:2:58, v/v/v/v) at flow rate of 1.0 ml/min. The detection
wavelength was 286 nm. Column temperature was main-
tained at 35 C during detection. For SalB preparations, the
linear concentration range were 0.75e15.0 mg/ml (r ¼ 0.9997),
the recovery rates ranged from 98% to 102% with relative
standard deviation (RSD) of less than 2%. And all RSD of the
intra-day and inter-day precision for SalB were below 2%.
2.3.2. Drug release test
Release tests were performed in rotating basket method USP
34 XXIII, apparatus II (ZRS-8G; Tianjin, China; basket method).
The release medium was 900 ml of distilled water, capsules
containing 25mg of SalB were put into the rotating basket and
immersed in the dissolution medium, the temperature was
maintained at 37  0.5 C and rotation rate was 100 rpm. At
predetermined time intervals, 5 ml of the dissolution solution
was withdrawn and substituted with fresh dissolution me-
dium. The samples were filtered through 0.22 mm filter and
analyzed by HPLC for SalB as described above.
2.4. Pharmacokinetic studies
2.4.1. Establishment of angina pectoris NZW rabbits
It showed [17,18] that rabbits have similar fat metabolism as
humans, compared to other animals rabbits are prone to form
atherosclerotic plague by high-fat diet, which lead to angina
pectoris. Atherosclerotic rabbit model was constructed to
evaluate the efficacy of formulations. Thirty healthy male
NZW rabbits (body weight 2.0  0.9 kg) were purchased from
Experimental Animal Center of China Pharmaceutical Uni-
versity (Nanjing, China). All experimental procedures were
reviewed and approved by the institutional animal ethical
committee and were in compliance with the National In-
stitutes of Health Guide for Care and Use of Laboratory Ani-
mals. The animals were housed in a standard-condition room
holding constant temperature and humidity (23 C, RH55%)
with a 12 h light/dark cycle. Rabbits were randomly divided
into two groups, controlled group (n ¼ 6) and model group
(n ¼ 24). The controlled group were fed normally, while the
model group were operated by subcutaneous injection of ho-
mocysteine thiolactone (20 mg/ml in 5% glucose solution,
daily 20w25 mg/kg), and raised on high-fat diet (10%choles-
terol, 5% lard, 5% egg yolk powder, 0.5% sodium cholate, 79.5%
ordinary feed) [19,20]. 8 weeks later, controlled group and 6
rabbits randomly from the model group were respectively
chosen to assess whether the stable angina pectoris had been
formed. The model formations were characterized by the
electrocardiogram (ECG), carotid color Doppler ultrasound
imaging (CDEI), coronary angiography (CAG) and aortic pa-
thology section HE staining.
2.4.2. Animal experiment
The model animals were fasted for 12 h with free access to
water before the experiment, and randomly divided into three
groups: (1) controlled group; (2) SalB-IRPs group; (3) SalB-
MPOPs group. The controlled group received a controlled
capsule containing blank pellets without SalB (n ¼ 6). SalB-IRPs and SalB-MPOPs at a dose equivalent to 250 mg/kg of
SalB were filled into gelatin capsules with a manual capsule
filling machine (CapsulCN, Zhejiang, China) and orally
administered to the group (2) and group (3) rabbits (n ¼ 6),
respectively. Blood samples (1 ml) were collected from auric-
ular vein with a heparinized tube at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12,
16, 24, 48 h after dosing. Plasma specimens were separated by
centrifugation at 3000 rpm for 10 min and stored at 20 C
until analysis.
2.4.3. Plasma sample extraction and analysis
Prior to extraction, frozen plasma samples were thawed at
ambient temperature. All the operations were protected from
light. Rabbits plasma (200 ml) was mixed with 30 ml of hydro-
chloric acid (2.5 mol/l). After adding 1 ml of ethyl acetate, the
acidifiedmixture was further acidified by vortexing vigorously
for 3 min. The samples were centrifuged at 3000 rpm for
10 min, the organic layer was collected. The same extraction
procedure was performed twice more and the organic phase
was collected and evaporated to dryness under a nitrogen
streamat 40 C. The residuewas reconstituted in 100 mL of 30%
methanolwith 0.01% formic acid. 20 mL of the supernatantwas
injected into the HPLC system for analysis, and the HPLC
conditions were identical to those in vitro.
2.4.4. Calibration curve
The SalB stock solution (50 mg/ml) was prepared in methanol.
The stock solution was diluted at different times to get the
working solutions, consisting of 0.50, 1.00, 2.00, 5.00, 10.00,
15.00 and 25.00 mg/ml SalB in rabbit plasma. 100 ml of these
serial dilutions were individually transferred into Eppendorf
tubes and the solvents were evaporated to dryness under ni-
trogen stream. 200 ml blank rabbit plasma was added into the
above tubes and the SalB concentration were determined
following the procedures mentioned in Section 2.4.3. A
regression equation between concentration of SalB (C) and the
corresponding peak area (A) was acquired.
2.4.5. Method validation
Method validation including specificity, recovery, inter-day
and intra-day precision was examined by HPLC.
2.5. Pharmacodynamics studies
SOD levels were detected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16,
24 and 48 h after administration. Specifically, 2 ml blood was
obtained from ear margin border vein of the three groups.
After being static for few moments, the upper serum was
removed and stored at 20 C for analysis. When tested, the
serum was melt and taken out 100 ml, SOD vitality was
determined by Xanthine oxidase performed according to re-
agent box provided method.
2.6. Data analysis and evaluation
2.6.1. Curves plots between plasma drug concentration and
time, SOD levels change and time
For the Sal-IRPs and Sal-MPOPs group, the curves were plotted
between mean plasma concentration and time; SOD blood
levels-rising and time.
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cording to the formula:
ðDSODÞt ¼ ðSODÞt  ðSODcontrolÞt (1)
Where DSOD is the change of SOD plasma levels, (SOD)t is SOD
plasma levels of Sal-IRPs or Sal-MPOPs, (SODcontrol)t is SOD
plasma levels of the control group at time t, respectively.
2.6.2. PD model fitting
The PD data were input in WinNonlin software to calculate E
for fitting the experimental results, which showed that the
optimal was Emax-model and the equation was as follows:
E ¼ Emax  Ce
Ce  EC50 (2)
Where, E is DSOD, the change of SOD levels; Emax is the SalB
maximum effect, Ce is the SalB plasma concentration in cen-
tral compartment, EC50 was SalB effect compartment con-
centration when the effect value was half of maximal effect
value.
2.6.3. PK parameters prediction and PKePD combination
model construction
Pharmacokinetic parameters, including Cmax, Tmax, t1/2, MRT,
AUC0et and AUC0eN, were calculated by compartmental and
non-compartmental analysis using the PKSolver (Version 1.0),
and themost suitable compartmentmodelwas determined by
the smallest Akaike information criterion (AIC) value [21,22].
Both the SalB-IRPs and SalB-MPOPs PK were fitted to one-
compartment models.
2.6.4. PKePD relationship
The central compartment drug concentration (Cp) and effect-
site drug concentration (Ce) were calculated by WinNonlin
software and expressed as following formulas respectively
[23]:
Cp ¼ FX0kaVdðka  k10Þ 

ek10t  ekat ¼ X0ka
v0ðka  k10Þ 

ekt  ekat
(3)
Ce ¼ X0kake0v0 

ekat
ðk10  kaÞðke0  kaÞ þ
ek10t
ðka  k10Þðke0  k10Þ
þ e
ke0t
ðka  ke0Þðk10  ke0Þ

(4)
where,X0 is dosage, F is the oral bioavailability,V is the central
chamber distribution volume, V0 is the quotient of V/F, K1e is
the transport rate constant from central compartment to ef-
fect compartment, Ke0 is the effect compartment elimination
rate constant. Other parameters are the same meaning with
those previously mentioned.
Moreover, ECT courses were plotted.2.7. Statistical analysis
All results were expressed as the mean  standard deviation
(SD) of six animals. Statistical analysis was performed using
two-tailed student’s t-test (SPSS, version 10.0). Statisticaldifferences were considered to be significant as P < 0.05 or
P < 0.01.3. Results and discussion
3.1. SalB-MPOPs and SalB-IRPs release profiles
SalB-MPOPs were successfully prepared [16]. The in vitro
release profiles of SalB-IRPs and SalB-MPOPs illustrated that
SalB can be fast released from the IRPs but slowly from the
MPOPs. Furthermore, the SalB-MPOPs was fitted to Zero order
model following studying drug release from SalB-MPOPs with
different dissolution kinetic model. SalB-MPOPS formulation
was usually prepared by coating semi-permeable membrane
(water insoluble materials) containing pore-forming agent
(water soluble materials) [24,25]. In the current work, EC
aqueous dispersion and PVA-PEG were taken as semi-
permeable membrane and pore-forming agent, respectively.
When the SalB-MPOPs contacted with aqueous environment,
the pore-forming agent dissolved and formed drug release
hole, where drug released at a low rate.3.2. Verification of model animals
As Fig. 2 depicted in ECG 2A1 and 2A2, themodel group showed
obvious depression of the ST segment and T wave inversion
compared with the normal group, which confirmed the
myocardial ischemia status.
The CDEI of rabbits indicated that the vessel wall was
smooth in the normal group of 2B1, and intimae-media
thickness was not seen. While the model groups’ CDEI of 2B2
indicated that the vessel wall was roughness visibly, and the
vascular intimae-media thickness was significant. These
phenomena confirmed that the athermanous plaque was
formed.
Coronary arteriography is the gold standard of angina
diagnosis clinically. Compared with the normal group of pic-
ture 2C1, the model group of picture 2C2 showed that the
anterior descending coronary artery occluded completely at
arrow 1, and the circumflex branch presented a bifurcate
lesion at arrow 2. The results displayed that the angina pec-
toris model was constructed successfully.
The NZW rabbit’s aortic arch pathology slice picture illus-
trated in 2D1 that the vascular wall was smooth for normal
NZW rabbits. While 2D2 displayed that abnormal protuberant
existed in the inner vascularwall and the texturewas loose for
model rabbits, which were different to normal rabbits. The
vascularwall ofmodel rabbit was stainedwith oil redO, which
further validated the lipid plaque’s formation. The induction
method was rapid and feasible, and the model animals can be
used for further study of PK and PD.3.3. Pharmacokinetics
3.3.1. Method validations
3.3.1.1. Specificity. Fig. 3 showed that SalB was well separated
from the matrix impurities under the HPLC conditions, with
retention times at 13.12 min, the resolution was greater than
Fig. 2 e The ECG of rabbits (2A1: Normal group; 2A2: Model group). The CDEI in the rabbit carotid artery (2B1: Normal group;
2B2: Model group). The CAG in the rabbit coronary artery (2C1: Normal group; 2C2: Model group). HE stained pathological
figures of rabbit aortic archs. (2D1: normal group; 2D2: Model group).
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was greater than 5000.
3.3.1.2. Recovery. The absolute recovery of SalB was calcu-
lated by the percentage of the valuemeasured in blank plasma
samples to the standard solutions in the same concentration,
and the value fluctuated from 80% to 86% at three concen-
trations tested as recorded in Table 1.
3.3.1.3. Range and linearity of the calibration curve. It showed
that there was a good linearity between concentration of SalB
(C) and the corresponding peak area (A). The linear range was
0.50e25 mg/ml, and the equation of calibration curve was
A ¼ 131864  C þ 224.5, with r ¼ 0.9986. Calaulating at three
times of the signal noise ratio, the detection limit of SalB was
10 ng/ml.
3.3.1.4. Inter-day and intra-day precision. The samples of
3.3.1.2 were also used to perform the precision tests. The
Inter-day precision was expressed as the relative standard
deviation (RSD) of HPLC peak area from 5 repeats in a single
run every other 2 h. The intra-day precisions were presented
at RSD of that by consecutive 5 days.
As was shown in Table 2, all the RSDs were below 10%
which were acceptable.3.3.2. PK analysis
As plotted in Fig. 4 the mean SalB plasma concentration and
time curves after single-dose administration in model ani-
mals and the related PK parameters were listed in Table 3.
As depicted in Fig. 4, the minimum plasma (Cmin) was
almost identical between SalB-MPOPs and SalB-IRPs, while
Cmax of SalB-MPOPs was significant lower than that of SalB-
IRPs, stating clearly that the fluctuation between Cmax and
Cmin was greatly reduced in SalB-MPOPs group. Compared
with SalB-IRPs, SalB-MPOPs had longer Tmax, longer MRT,
larger AUC0et and AUC0eN. These results indicated that the
SalB absorption was at a slow rate, and the duration of SalB-
MPOPS was longer than that of SalB-IRPs. The bioavailability
of SalB-MPOPs might be higer than that of SalB-IRPs.3.4. Effect-time course
SalBcanenhanceSODvitality toprotectmuscle cell [26]. SoSOD
levels as continuously PD index were detected. Fig. 5 displayed
the temporal profiles of DSOD level after oral administration of
SalB-IRPs and SalB-MPOPs in AP-NZW rabbits. In SalB-IRPS
group the (DSOD)max value was 104 U/ml at 8 h, then DSOD
value decreased quickly, while in SalB-MPOPs group (DSOD)max
was 56U/ml at 10h and theDSODvalue reduced gradually. This
Table 1 e absolute recovery of SalB in plasma (mean ± SD,
n[ 3).
C (mg/ml) Recovery (%) RSD (%)
0.50 80.34  6.66 8.29
5.00 83.45  3.94 4.72
25.00 86.36  4.56 5.28
Fig. 3 e Typical HPLC chromatograms: (A) blank rabbit plasma sample; (B) rabbit plasma spiked with SalB; (C) rabbit plasma
sample after oral administration of SalB pellets.
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also thewhole effect timewasprolonged for SalB-MPOPsgroup,
compared with SalB-IRPs group. These might be mirrored by
the corresponding PK parameters.3.5. PKePD relationships
The PK, PD data were input into the WinNonlin software, and
the correlation parameters were shown in Table 4.
Table 2eMeasurement precision for SalB in spiked rabbit
plasma (mean ± SD, n[ 5).
Concentration
(mg/ml)
Inter-day Intra-day
Mean
(mg/ml)
RSD
(%)
Mean
(mg/ml)
RSD
(%)
0.50 0.47  0.03 6.38 0.48  0.03 6.25
5.00 5.03  0.231 4.59 5.08  0.220 4.33
25.00 25.08  2.042 8.14 24.09  1.950 8.95
Table 3 e The pharmacokinetic parameters of SalB for
SalB-IRPs and SalB-MPOPs after single oral
administration in AP-NZW rabbits. (mean ± SD, n[ 6).
Parameters (unit) SalB-IRPs SalB-MPOPs
Tmax (h) 1.35  0.823 10.00  0.415
Cmax (mg/ml) 8.45  0.712 3.98  0.092
MRT (h) 3.02  1.451 15.94  0.512
AUC0et (mg$h/ml) 31.92  3.289 42.02  4.534a
AUC0eN (mg$h/ml) 32.20  3.865 43.43  7.457a
aP < 0.01 versus SalB-IRPs.
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were remarkably higher of IR group than that of SalB-MPOPs
group, while Ke0 value of SalB-MPOPs group was notably
higher than that of SalB-IRPS group, which indicated that drug
from SalB-MPOPs formulations was easier to reach balance
between central compartment and effect compartment, and
the lag time was short. In addition, significant differences
were found for area under effectetime curve from 0 to 24 h
(AUE0e24 h) and from 0 to infinity (AUE0eN) between SalB-IRPs
and SalB-MPOPs formulations, which might be ascribed to
different AUC0e24 h and AUC0eN. A direct correlation between
the magnitude of SOD value (AUE) and system drug exposure
(AUC) was speculated, and so was the relationship between
the plasma drug concentration and effect [2]. Currently, re-
searches on relationship between the plasma drug concen-
tration and effect are extremely rare, which always
hypothesizes a direct correlation [2].
3.6. ECT curves
In order to find the probable differences of ECT curves be-
tween SalB-IRPs and SalB-MPOPs, hysteresis loops were
plotted using the present nonsteady-state and time-
dependent data of central compartments concentration (Cp)
or effect site concentration (Ce) at different time points.
In Fig. 6A, a counter-clockwise hysteresis loop displayed
the relationship of the time course between SalB concentra-
tion in plasma or effect site and the SOD value following SalB-
IRPs administration. From Fig. 6A, It can be seen that effectFig. 4 e Mean SalB plasma concentration-time curves of
SlaB-IRPs and SalB-MPOPs in serum after single oral
administration to AP-NZW rabbits (mean ± SD, 250 mg/kg,
n [ 6).was lagged behind the blood concentration. These phenom-
ena were probably because that SalB fast released from SalB-
IRPs in vivo and the plasma concentrations increased rapidly
accordingly, while timewas needed for concentration to reach
a balance in effect sites of cardiac tissue and vascular smooth
muscle, so the effect lagged behind the blood concentration.
In addition, ECpT and ECeT curves did not coincide completely,
the dissociation of time courses of plasma concentration and
effect might be attributed to that the plasma distribution was
disequilibrium between center and effect compartments. The
relationship between the concentration and effect was not
correlated to the time course, which indicated that it did not
go in one between the plasma center and the effect
compartment.
In Fig. 6B, a clockwise hysteresis loop presented that the
relationship of the time course between plasma or effect site
SalB concentration and the SOD value following SalB-MPOPs’
administration. It indicated that SalB plasma concentrations
and effect were always synchronized, namely, during the
whole time the concentration and effect were highly corre-
lated. The loop for central compartment was almost over-
lappedwith that for effect compartment, which indicated that
plasma drug concentration and effect-site concentration bal-
ance were built more rapidly, and the center and the effect
compartments were attributed to the same site. SalB released
slowly from SalB-MPOPs formulation, and the plasma drug
concentration curves were steady leading drug concentration
to reach rapid equilibrium between plasma compartment andFig. 5 e Plots of DSOD versus time after a single oral
administration of SalB-IRPs and SalB-MPOPs formulation
to AP-NZW (mean ± SD, 250 mg/kg, n [ 6).
Table 4 e PKePD parameters of SalB-IRPs and SalB-
MPOPs (mean ± SD, n[ 6).
Parameters (unit) Sal-IRPs Sal-MPOPs
Emax (U/ml) 1037.36  7.46 288.90  17.21a
EC50 (mg/ml) 31.59  0.75 10.52  0.67a
Ke0 (1/h) 0.093  0.016 1.89  0.15a
t1/2eq(h) 7.48  1.07 0.37  0.016a
AUE0et(h$U/ml) 970.75  15.47 1268.25  2.34a
AUE0eN(h$U/ml) 1046.33  16.33 1274.60  2.51a
aP < 0.01 versus SalB-IRPs The parameter t1/2eq is the equilibration
half time between the plasma and the effect compartment and it is
equal to ln2/Ke0.
Fig. 6 e Temporal Plots of SOD versus SalB concentration
after single oral administration of SalB-IRPs and and SalB-
MPOPs formulation to AP-NZW rabbits (250 mg/kg, n [ 6).
(A) SalB-IRPs and (B) SalB-MPOPs. The arrow indicates the
time flow after oral administration. Cp: central
compartment drug concentration, Ce: effect compartment
drug concentration.
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response [27].
Mechanism-based PKePD model aims at the prediction of
exposureeresponse relationships. Exposure and response are
expressed as the time course of the drug concentration in
plasma and the drug-effect intensity, respectively [28]. When
the drug target site is outside the plasma, drug exposure can’t
reflect the drug response. PKePD model provides a deeper
understanding of drug action, though the approach was
inconvenient because of simultaneous determination of drug
concentration in target tissue and corresponding efficacy at
multiple time points [29]. It is of particular importance to
design and optimize rational dosage forms, so the studies
havemade a contribution to drug discovery and development.4. Conclusion
In this present work, the in vitro release, PK, PD and PKePD
relationships for SalB-MPOPs were reported, compared with
those for SalB-IRPs. The provided analysis method of SalB in
angina pectoris model rabbit plasma was feasible. The PKePD
relationships studies manifested that the central compart-
ment and effect compartment of SalB-MPOPs were in the
same site while SalB-IRPs’ were not. In summary, the present
study established a nonsteady-state and time-dependent
multiple PKePD model of a single dose of SalB-IRPs and
SalB-MPOPs in AP-NZW rabbits. The fast and short-lasting
counter-clockwise hysteresis loop model well represents the
relationship of the time course for SalB-IRPs, while the
delayed and long-lasting clockwise hysteresis loopmodel well
represents that for SalB-MPOPs. The SalB-MPOPs formulation
was thought as a better drug delivery system than SalB-IRPs
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